U.S. markets close in 20 minutes

Takara Bio Inc. (4974.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
Add to watchlist
1,945.00-41.00 (-2.06%)
At close: 03:15PM JST

Takara Bio Inc.

7-4-38 Nojihigashi
Kusatsu 525-0058
81 77 565 6920

Full Time Employees1,539

Key Executives

NameTitlePayExercisedYear Born
Mr. Hisashi OhmiyaChairmanN/AN/A1943
Mr. Koichi NakaoCEO, Pres & Representative DirectorN/AN/A1962
Dr. Yoh Hamaoka Ph.D.Sr. Exec. Officer & DirectorN/AN/AN/A
Mr. Tsuyoshi MiyamuraSr. Exec. Officer & DirectorN/AN/AN/A
Mr. Junichi Mineno Ph.D.VP, Exec. Officer & DirectorN/AN/AN/A
Masanari Kitagawa Ph.D.Exec. OfficerN/AN/AN/A
Mr. Masanobu Kimura M.S., MS, R.Ph.Exec. Officer & DirectorN/AN/AN/A
Mutsumi Sano Ph.D.Sr. Exec. OfficerN/AN/AN/A
Katsuhiko KusakabeManaging Exec. OfficerN/AN/AN/A
Mr. Andrew Farmer Ph.d.Head of R&DN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.


Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Corporate Governance

Takara Bio Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.